Such engineering of an antibody, so that it is capable of binding to both 4-1BB and another target that is known to be commonly upregulated in and associated with tumors, sought to increase specificity of the 4-1BB activation by localizing the agonistic antibody and the consequent immune stimulation to the tumor environment. Here, TNFRSF9 is linked to neoplasm.